Compile Data Set for Download or QSAR
Report error Found 82 Enz. Inhib. hit(s) with all data for entry = 12908
TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739683((R)-1-(3-((3-(cyclopent-1-en-1-yl)-1H-pyrrolo[2,3-...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739682((R)-1-(3-((3-cyclopentyl-1H-pyrrolo[2,3-b]pyridin-...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739681(1-((3R)-3-((5-(2,2-difluorocyclopropyl)-7H- pyrrol...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739680(1-((R)-3-((5-((1R,2R)-2-(methoxymethyl)cyclopropyl...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739678(1-((2S,5R)-5-((5-(cyclopropylmethyl)-7H-pyrrolo[2,...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739677((R)-1-(3-((5-(1-methylcyclopropyl)-7H-pyrrolo[2,3-...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739676((R)-1-(3-((3-(cyclopentylmethyl)-1H-pyrrolo[2,3- b...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739690(1-((2S,5R)-5-((5-((3-ethylcyclopentyl)methyl)-7H- ...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739689(1-((2S,5R)-5-((3-(cyclopropylmethyl)-1H-pyrrolo[2,...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739688(1-((2S,5R)-5-((3-(cyclopropanecarbonyl)-1H- pyrrol...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739686(1-((2S,5R)-5-((5-(cyclopropanecarbonyl)-7H- pyrrol...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739685(tert-butyl 4-(((3R,6S)-1-acryloyl-6-methylpiperidi...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739684(1-((2S,5R)-5-((5-cyclopentyl-7H-pyrrolo[2,3- d]pyr...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739662((R)-1-(3-((3-(cyclopropanecarbonyl)-1H-pyrrolo[2,3...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739674((R)-1-(3-((5-(cyclobutylmethyl)-7H-pyrrolo[2,3- d]...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739673((R)-1-(3-((3-(cyclopropylmethyl)-1H-pyrrolo[2,3- b...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739672((R)-1-(3-((5-(cyclopropylmethyl)-7H-pyrrolo[2,3- d...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739671(1-((2S,5R)-5-((5-(cyclobutanecarbonyl)-7H- pyrrolo...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739670(isobutyl 4-(((3R,6S)-1-acryloyl-6-methylpiperidin-...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739667((R)-1-(3-((3-(1-methylcyclopropane-1-carbonyl)-1H-...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739713((E)-1-((2S,5R)-5-((5-((R)-2,2-difluorocyclopropyl)...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739709(1-((2S,5R)-5-((5-((1R,3R)-2,2-difluoro-3- methylcy...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739708(1-((2S,5R)-5-((5-((1S,3S)-2,2-difluoro-3- methylcy...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739723(1-((2R)-5-((5-((S)-2,2-difluorocyclopropyl)-7H- py...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739721(1-((2S,5R)-5-((5-((S)-2,2-difluorocyclopropyl)-7H-...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739718(1-((2S,5S)-5-((5-((R)-2,2-difluorocyclopropyl)-7H-...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739699(1-((2S,5R)-5-((5-((1R,2R)-2- (methoxymethyl)cyclop...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739698(1-((2S,5R)-5-((5-(2-(methoxymethyl)cyclopropyl)-7H...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739696(1-((2S,5S)-5-((5-(cyclopropylmethyl)-7H-pyrrolo[2,...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739693(1-((2R,5S)-5-((5-(cyclopropylmethyl)-7H-pyrrolo[2,...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739692(1-(5-((5-(cyclopropylmethyl)-7H-pyrrolo[2,3- d]pyr...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739707(1-((2S,5R)-5-((5-((R)-2,2-difluoro-3,3- dimethylcy...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739706(1-((2S,5R)-5-((5-((1R,3S)-2,2-difluoro-3- methylcy...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739705(1-((2S,5R)-5-((5-((1S,3R)-2,2-difluoro-3- methylcy...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739704(1-((2S,5R)-5-((5-(2,2-difluoro-1-methylcyclopropyl...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739703(1-((2S,5R)-5-((5-((S)-2,2-difluorocyclopropyl)-7H-...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739702(1-((2S,5R)-5-((5-((R)-2,2-difluorocyclopropyl)-7H-...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739701(1-((2S,5R)-5-((5-(2,2-difluorocyclopropyl)-7H- pyr...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739700(1-((2S,5R)-5-((5-((1S,2S)-2- (methoxymethyl)cyclop...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739731(ethyl 5-((1-acryloylpiperidin-4-yl)amino)-1H-pyrro...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739730(1-((R)-3-((5-((1S,5R)-6,6-difluorobicyclo[3.1.0]he...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739729(1-((R)-3-((5-((1R,5S)-6,6-difluorobicyclo[3.1.0]he...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739728(1-((2S,5R)-5-((3-((1R,2R)-2- (methoxymethyl)cyclop...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739726(1-((2S,5R)-5-((3-((S)-2,2-difluorocyclopropyl)-1H-...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739725(1-((2S,5R)-5-((3-((R)-2,2-difluorocyclopropyl)-1H-...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739735(1-(4-((7-(cyclobutanecarbonyl)-5H-pyrrolo[2,3-b]py...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739734(1-(4-((7-(cyclopropanecarbonyl)-5H-pyrrolo[2,3-b]p...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739732(ethyl 2-((1-acryloylpiperidin-4--yl)amino)-5H-pyrr...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739657(isopropyl 4-(((3R,6S)-1-acryloyl-6-methylpiperidin...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM739656(propyl 4-(((3R,6S)-1-acryloyl-6-methylpiperidin-3-...)
Affinity DataIC50: 10nMAssay Description:The ability of candidate compounds to interact with JAK3 is quantitated by a mobility shift assay using an LC3000 instrument developed by Caliper Lif...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/11/2025
Entry Details
US Patent

Displayed 1 to 50 (of 82 total ) | Next | Last >>
Jump to: